AzurRx BioPharma Inc to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis - Conference Call Transcript

Mar 31, 2021 / 08:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the AzurRx BioPharma, Inc. Webcast and Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Jason Rando, with the Tiberend Strategic Advisors. Please go ahead.

Jason Rando - Tiberend Strategic Advisors, Inc. - COO & EVP

Good afternoon, and thank you for joining today's call to discuss AzurRx BioPharma's Phase IIb OPTION 2 clinical trial results and MS1819 development plan.

Before we begin, I would like to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties and are subject to changes at any time, including, but not limited to, statements about AzurRx' expectations regarding future operating results. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations. Actual results may

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot